Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Urinary biomarkers of kidney diseases in HIV-infected children.

Perazzo S, Soler-García ÁA, Hathout Y, Das JR, Ray PE.

Proteomics Clin Appl. 2015 Jun;9(5-6):490-500. doi: 10.1002/prca.201400193. Review.

2.

Chronic hepatitis B virus infection and pregnancy.

Kumar M, Singh T, Sinha S.

J Clin Exp Hepatol. 2012 Dec;2(4):366-81. doi: 10.1016/j.jceh.2012.09.001. Epub 2012 Sep 20. Review.

3.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC; HIV Medicine Association of the Infectious Diseases Society of America.

Clin Infect Dis. 2014 Nov 1;59(9):e96-138. doi: 10.1093/cid/ciu617. Epub 2014 Sep 17.

4.

Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection.

Margolick JB, Jacobson LP, Schwartz GJ, Abraham AG, Darilay AT, Kingsley LA, Witt MD, Palella FJ Jr.

PLoS One. 2014 Feb 7;9(2):e86311. doi: 10.1371/journal.pone.0086311. eCollection 2014.

5.

Trends in hospitalizations among children and young adults with perinatally acquired HIV.

Berry SA, Gebo KA, Rutstein RM, Althoff KN, Korthuis PT, Gaur AH, Spector SA, Warford R, Yehia BR, Agwu AL; HIV Research Network.

Pediatr Infect Dis J. 2014 May;33(5):488-94. doi: 10.1097/INF.0000000000000126.

6.

Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?

Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Gordon CM, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team.

Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.

7.

Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.

Lucey JM, Hsu P, Ziegler JB.

BMJ Case Rep. 2013 Jul 9;2013. pii: bcr2013008674. doi: 10.1136/bcr-2013-008674.

8.

Kidney disease in children and adolescents with perinatal HIV-1 infection.

Bhimma R, Purswani MU, Kala U.

J Int AIDS Soc. 2013 Jun 18;16:18596. doi: 10.7448/IAS.16.1.18596. Review.

9.

Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Purswani M, Patel K, Kopp JB, Seage GR 3rd, Chernoff MC, Hazra R, Siberry GK, Mofenson LM, Scott GB, Van Dyke RB; Pediatric HIVAIDS Cohort Study.

Pediatr Infect Dis J. 2013 May;32(5):495-500. doi: 10.1097/INF.0b013e31827f4eff.

10.

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.

Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team.

PLoS Med. 2012;9(5):e1001217. doi: 10.1371/journal.pmed.1001217. Epub 2012 May 15.

11.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

12.

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD, Liu N, Lujan-Zilbermann J, Baker A, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team.

Clin Infect Dis. 2012 Apr;54(7):1013-25. doi: 10.1093/cid/cir968. Epub 2012 Jan 19.

13.
14.

Renal disease in HIV-infected individuals.

Phair J, Palella F.

Curr Opin HIV AIDS. 2011 Jul;6(4):285-9. doi: 10.1097/COH.0b013e3283476bc3. Review.

15.

Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.

Alsauskas ZC, Medapalli RK, Ross MJ.

Expert Opin Pharmacother. 2011 Apr;12(5):691-704. doi: 10.1517/14656566.2011.535518. Epub 2011 Jan 21. Review.

16.

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens.

Manosuthi W, Mankatitham W, Lueangniyomkul A, Prasithsirikul W, Tantanathip P, Suntisuklappon B, Narkksoksung A, Nilkamhang S, Sungkanuparph S.

AIDS Res Ther. 2010 Oct 11;7:37. doi: 10.1186/1742-6405-7-37.

Supplemental Content

Support Center